Suzanne George

Suzanne George at Dana-Farber is a GIST and sarcoma specialist who has contributed to trials establishing regorafenib and ripretinib as standard options for later-line GIST. Her research on molecular characterization of imatinib-resistant GIST and mutation-specific drug sensitivity has advanced precision treatment sequencing in GIST, informing which patients benefit from switching to alternative TKIs versus fourth-line options.